Cachexia is an adverse effect of prostate cancer (PCa) characterized by skeletal muscle loss which significantly impacts mortality and quality of life. Recently, proteolysis-inducing factor (PIF) mediated activation of the ubiquitin proteasome system has been identified as a potential target for treating cachexia. Oncologists encourage nutritional and physical intercession to improve outcomes, however, it is unclear how these interventions impact PIF activity. PURPOSE: To test the hypothesis that Nexrutine® (a natural bark extract of the Amur cork tree with anti-inflammatory capabilities) and exercise can independently attenuate muscle loss in a transgenic adenocarcinoma of mouse prostate (TRAMP) model by modulating PIF. METHODS: Forty-five, ten-week old male TRAMP mice were randomized to either control (Con), Nexrutine® (Nex; 600 mg/kg pelleted into chow) or exercise (Ex; voluntary wheel running), for up to 20-weeks. Mice were weighed and sacrificed at 4, 8, 12 and 20 weeks at which time gastrocnemius muscle was collected, weighted and frozen until analysis. Intramuscular PIF and ubiquitin (Ub) were quantified using commercially bought ELISA kits. An analysis of variance was conducted using a Tukey’s post hoc test with significance set at pRESULTS: Analysis of gastrocnemius mass revealed significance (F=4.159, p=0.02), with both Nex and Ex treatment groups having greater mass compared to Con (pCONCLUSION: Results suggest that Nex can mimic the effects of Ex in preventing muscle loss in TRAMP mice through reduction of PIF and preservation of muscle mass. While exercise reduced downstream Ub, the mechanism by which Nex elicits a protective effects remains unknown.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.